

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KARBE FRANK</u> <hr/> (Last) (First) (Middle) <u>C/O TEKMIRA PHARMACEUTICALS CORP.</u> <u>SUITE 100, 8900 GLENLYON PARKWAY</u> <hr/> (Street) <u>BURNABY A1 V5J 5J8</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/01/2015</u>	3. Issuer Name and Ticker or Trading Symbol <u>TEKMIRA PHARMACEUTICALS Corp [TKMR]</u> <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Shares</u>	<u>5,000</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Director Stock Option (Right to Buy)</u>	<u>01/28/2010</u>	<u>01/27/2020</u>	<u>Common Shares</u>	<u>5,000</u>	<u>3.85⁽¹⁾</u>	<u>D</u>	
<u>Director Stock Option (Right to Buy)</u>	<u>08/10/2011</u>	<u>08/09/2021</u>	<u>Common Shares</u>	<u>5,000</u>	<u>2.4⁽¹⁾</u>	<u>D</u>	
<u>Director Stock Option (Right to Buy)</u>	<u>12/23/2011</u>	<u>12/22/2021</u>	<u>Common Shares</u>	<u>5,000</u>	<u>1.7⁽¹⁾</u>	<u>D</u>	
<u>Director Stock Option (Right to Buy)</u>	<u>12/10/2012</u>	<u>12/09/2022</u>	<u>Common Shares</u>	<u>5,000</u>	<u>5.15⁽¹⁾</u>	<u>D</u>	
<u>Director Stock Option (Right to Buy)</u>	<u>05/08/2014</u>	<u>05/07/2024</u>	<u>Common Shares</u>	<u>17,500</u>	<u>12.52⁽¹⁾</u>	<u>D</u>	
<u>Warrants</u>	<u>02/29/2012</u>	<u>03/01/2017</u>	<u>Common Shares</u>	<u>2,500</u>	<u>2.6⁽¹⁾</u>	<u>D</u>	

Explanation of Responses:

1. Expressed in Canadian dollars.

Remarks:/s/ FranK Karbe12/31/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.